LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies.

Nassabein, Rami / Younan, Rami / Loungarath, Rasmy / Mercier, Frederic / Dagbert, Francois / Aubin, Francine / Ayoub, Jean Pierre / Tehfé, Mustapha

Canadian journal of surgery. Journal canadien de chirurgie

2022 Volume 65, Issue 3, Page(s) E342–E351

Abstract: Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is an extensive ... ...

Abstract	Background: Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has recently shown promise for the treatment of patients with various types of peritoneal carcinomatosis (PC). However, it is an extensive procedure that is associated with a variety of morbidities. We evaluated the safety and clinical outcomes of CRS-HIPEC performed at our centre. Methods: Patients with abdominal malignancies who underwent CRS-HIPEC between February 2005 and December 2018 at the Centre hospitalier de l'Université de Montréal (CHUM) were retrospectively reviewed. Results: A total of 141 patients were identified (66 with appendiceal cancer, 62 with colorectal cancer, 10 with mesothelioma and 3 with small intestinal tumours). The median age was 55 years. Median overall survival (OS) was not reached for patients with appendiceal tumours; it was 38.3 months for colorectal cancers. Among patients with colorectal cancer, survival was significantly better for those who received intraperitoneal HIPEC with oxaliplatin (74.9 mo) compared with mitomycin C (29.1 mo) ( Conclusion: CRS-HIPEC can be performed with acceptable morbidity in patients with PC. These results validate the outcomes of previously reported trials, but further prospective trials are warranted to determine which patients will most benefit from the addition of HIPEC to CRS.
MeSH term(s)	Appendiceal Neoplasms/drug therapy ; Canada ; Chemotherapy, Cancer, Regional Perfusion ; Colorectal Neoplasms/pathology ; Combined Modality Therapy ; Cytoreduction Surgical Procedures/adverse effects ; Humans ; Hyperthermia, Induced ; Hyperthermic Intraperitoneal Chemotherapy ; Middle Aged ; Peritoneal Neoplasms/drug therapy ; Retrospective Studies ; Survival Rate
Language	English
Publishing date	2022-05-17
Publishing country	Canada
Document type	Journal Article
ZDB-ID	410651-9
ISSN	1488-2310 ; 0008-428X
ISSN (online)	1488-2310
ISSN	0008-428X
DOI	10.1503/cjs.004320
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC).

Nassabein, Rami / Gaudreau, Pierre-Olivier / Belkaid, Wiam / Florescu, Marie / Blais, Normand

Cancer treatment and research communications

2021 Volume 28, Page(s) 100421

MeSH term(s)	Aged ; Albumins/pharmacology ; Albumins/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use
Chemical Substances	130-nm albumin-bound paclitaxel ; Albumins ; Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2021-06-06
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2468-2942
ISSN (online)	2468-2942
DOI	10.1016/j.ctarc.2021.100421
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Arterial thrombosis and coronavirus disease 2019 in a patient with cancer.

Nassabein, Rami / Routy, Bertrand / Blais, Normand / Ayoub, Jean-Pierre / Tehfé, Mustapha

European journal of cancer (Oxford, England : 1990)

2020 Volume 134, Page(s) 1–2

MeSH term(s)	Anticoagulants ; Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections ; Humans ; Neoplasms ; Pandemics ; Pneumonia, Viral ; Rivaroxaban ; SARS-CoV-2 ; Thrombosis ; Venous Thromboembolism
Chemical Substances	Anticoagulants ; Rivaroxaban (9NDF7JZ4M3)
Keywords	covid19
Language	English
Publishing date	2020-05-18
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2020.05.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 Impact on Diagnosis and Staging of Colorectal Cancer: A Single Tertiary Canadian Oncology Center Experience.

Castonguay, Mathias / El Sayed, Rola / Richard, Corentin / Vachon, Marie-France / Nassabein, Rami / Charpentier, Danielle / Tehfé, Mustapha

Current oncology (Toronto, Ont.)

2022 Volume 29, Issue 5, Page(s) 3282–3290

Abstract: Background: Public health measures have imposed drastic reductions in cancer screening programs at the beginning of the COVID-19 pandemic, with an unknown impact on the diagnosis and staging of colorectal cancer (CRC).: Methods: Newly diagnosed CRC ... ...

Abstract	Background: Public health measures have imposed drastic reductions in cancer screening programs at the beginning of the COVID-19 pandemic, with an unknown impact on the diagnosis and staging of colorectal cancer (CRC). Methods: Newly diagnosed CRC cases at the Centre Hospitalier de l'Université de Montréal (CHUM) were divided into two groups according to the timeline: pre-pandemic (1 January 2018-12 March 2020), and pandemic (13 March 2020-30 June 2021) periods. Colonoscopy, surgery, and staging at diagnosis during the pandemic period were compared to the pre-pandemic period. Results: 254 CRC diagnoses were made during the pre-pandemic period in comparison to 125 during the pandemic period. Mean diagnosis rates were lower in the pandemic period (7.8 vs. 9.8 diagnoses/month, Conclusion: In our center, the COVID-19 pandemic resulted in a decreased rate of CRC diagnosis and increased endoscopic delays without affecting the rate of advanced stage disease. Delays to surgery were quite similar once the CRC diagnosis was established.
MeSH term(s)	COVID-19/epidemiology ; Canada ; Colonoscopy ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/epidemiology ; Humans ; Pandemics
Language	English
Publishing date	2022-05-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol29050268
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.

Proulx-Rocray, Francis / Routy, Bertrand / Nassabein, Rami / Belkaid, Wiam / Tran-Thanh, Danh / Malo, Julie / Tonneau, Marion / Ouarzadi, Omar El / Florescu, Marie / Tehfe, Mustapha / Blais, Normand

Cancer treatment and research communications

2023 Volume 37, Page(s) 100767

Abstract: Background: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in TP53, STK11 and KEAP1 as well as the NLR showed that ...

Abstract	Background: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in TP53, STK11 and KEAP1 as well as the NLR showed that they may predict the benefit of ICIs. Patients & methods: This is a retrospective study of patients with NSCLC treated with ICIs at the CHUM between July 2015 and June 2020. OS and PFS were compared using Kaplan-Meier and logrank methods. Co-mutations in TP53, STK11 and KEAP1 as well as the NLR were accounted for. ORR and safety were compared using Wald method. Results: From 100 patients with known KRAS status, 50 were mutated (KRAS Conclusion: STK11 Microabstract: Response of NSCLC to immunotherapy is not easily predictable. We conducted a retrospective study in 100 patients with NSCLC and a known KRAS status. By accounting for different co-mutations, KRAS mutation was found to be associated with a better median overall survival in STK11 and KEAP1 wild-type tumors (21.1 vs 15.8, p = 0.15). NLR was impacted by STK11, but not KEAP1 mutation, suggesting a difference in their resistance mechanism.
MeSH term(s)	Humans ; Prognosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Kelch-Like ECH-Associated Protein 1/genetics ; NF-E2-Related Factor 2/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Protein Serine-Threonine Kinases/genetics ; Immunotherapy ; Mutation ; Tumor Suppressor Protein p53/genetics
Chemical Substances	Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; Kelch-Like ECH-Associated Protein 1 ; NF-E2-Related Factor 2 ; Protein Serine-Threonine Kinases (EC 2.7.11.1) ; TP53 protein, human ; Tumor Suppressor Protein p53 ; KRAS protein, human ; KEAP1 protein, human ; STK11 protein, human (EC 2.7.11.1)
Language	English
Publishing date	2023-10-10
Publishing country	England
Document type	Journal Article
ISSN	2468-2942
ISSN (online)	2468-2942
DOI	10.1016/j.ctarc.2023.100767
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Arterial thrombosis and coronavirus disease 2019 in a patient with cancer

Nassabein, Rami / Routy, Bertrand / Blais, Normand / Ayoub, Jean-Pierre / Tehfé, Mustapha

Eur J Cancer

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #276893
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

El-Amm, Joelle / Nassabein, Rami / Aragon-Ching, Jeanny B

Cancer management and research

2017 Volume 9, Page(s) 299–306

Abstract: Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre- ... ...

Abstract	Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. There has been a lot of interest and emphasis in the evaluation of patient-related outcomes (PROs) as it relates to quality of life, pain, adverse events, fatigue, and among others, in the use of different agents that have been shown to improve survival. This review examines the companion PROs in conjunction with abiraterone acetate use. This is particularly relevant since PROs are increasingly viewed as a key metric for drug label claims in granting approval across regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency.
Language	English
Publishing date	2017-07-11
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2508013-1
ISSN	1179-1322
ISSN	1179-1322
DOI	10.2147/CMAR.S139305
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Outcomes of Older Patients with Resectable Colorectal Liver Metastases Cancer (CRLM): Single Center Experience.

Nassabein, Rami / Mansour, Laura / Richard, Corentin / Vandenbroucke-Menu, Franck / Aubin, Francine / Ayoub, Jean-Pierre / Dagenais, Michel / Lapointe, Real / Letourneau, Richard / Plasse, Marylène / Roy, André / Turcotte, Simon / Tehfe, Mustapha

Current oncology (Toronto, Ont.)

2021 Volume 28, Issue 3, Page(s) 1899–1908

Abstract: Surgery is the only potential curative option of CRLM if resectable. The curative approach in patients over 70 years old is challenging mainly because of comorbidities and other geriatric syndromes. Herein, we report outcomes of older patients with ... ...

Abstract	Surgery is the only potential curative option of CRLM if resectable. The curative approach in patients over 70 years old is challenging mainly because of comorbidities and other geriatric syndromes. Herein, we report outcomes of older patients with resectable CRLM in our center. We retrospectively analyzed characteristics and outcomes of older patients with CRLM operated at "Centre Hospitalier de l'Université de Montréal" (CHUM) between 2010 and 2019. We identified 210 patients aged ≥70 years with a median age of 76 (range: 70-85). CRLM were synchronous in 56% of patients. Median disease-free survival (DFS) was 41.3 months. Median overall survival (OS) was 62.2 months and estimated 5-year survival rate was 51.5% similar to those of younger counterparts. Patients with metachronous CRLM had a trend to a higher OS compared to those with synchronous disease (67.2 vs. 58.7 months;
MeSH term(s)	Aged ; Colorectal Neoplasms ; Disease-Free Survival ; Hepatectomy ; Humans ; Liver Neoplasms/surgery ; Retrospective Studies
Language	English
Publishing date	2021-05-18
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol28030176
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Pan-Canadian Validation Study for the Detection of

Selvarajah, Shamini / Plante, Sophie / Speevak, Marsha / Vaags, Andrea / Hamelinck, Darren / Butcher, Martin / McCready, Elizabeth / Grafodatskaya, Daria / Blais, Normand / Tran-Thanh, Danh / Weng, Xiaoduan / Nassabein, Rami / Greer, Wenda / Walton, Ryan N / Lo, Bryan / Demetrick, Doug / Santos, Stephanie / Sadikovic, Bekim / Zhang, Xiao /

Zhang, Tong / Spence, Tara / Stockley, Tracy / Feilotter, Harriet / Joubert, Philippe

JTO clinical and research reports

2021 Volume 2, Issue 8, Page(s) 100212

Abstract: Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the : Methods: In phase 1, commercial reference standards were distributed to participating clinical laboratories, to use their existing ... ...

Abstract	Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the Methods: In phase 1, commercial reference standards were distributed to participating clinical laboratories, to use their existing platforms for mutation detection. Baseline performance characteristics were established using known and blinded engineered plasma samples spiked with predetermined concentrations of T790M, L858R, and exon 19 deletion variants. In phase II, peripheral blood collected from local patients with known Results: All laboratories in phase 1 detected the variants at 0.5 % and 5.0 % allele frequencies, with no false positives. In phase 2, the concordance with the reference laboratory for detection of both the primary and resistance mutation was high, with next-generation sequencing and droplet digital polymerase chain reaction exhibiting the best overall concordance. Data also suggested that the ability to detect mutations at clinically relevant limits of detection is generally not platform-specific, but rather impacted by laboratory-specific practices. Conclusions: Discrepancies among sending laboratories using the same assay suggest that laboratory-specific practices may impact performance. In addition, a negative or inconclusive ctDNA test should be followed by tumor testing when possible.
Language	English
Publishing date	2021-07-13
Publishing country	United States
Document type	Journal Article
ISSN	2666-3643
ISSN (online)	2666-3643
DOI	10.1016/j.jtocrr.2021.100212
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.

The oncologist

2020 Volume 26, Issue 4, Page(s) e597–e602

Abstract: Background: Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD*2A polymorphism is one of the most studied variants. The ... ...

Abstract	Background: Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD2A polymorphism is one of the most studied variants. The study objective was to document the impact of implementing this test in routine clinical practice. Methods:* We retrospectively performed chart reviews of all patients who tested positive for a heterozygous or homozygous DPYD2A mutation in samples obtained from patients throughout the province of Quebec, Canada. Results:* During a period of 17 months, 2,617 patients were tested: 25 patients tested positive. All were White. Twenty-four of the 25 patients were heterozygous (0.92%), and one was homozygous (0.038%). Data were available for 20 patients: 15 were tested upfront, whereas five were identified after severe toxicities. Of the five patients confirmed after toxicities, all had grade 4 cytopenias, 80% grade ≥3 mucositis, 20% grade 3 rash, and 20% grade 3 diarrhea. Eight patients identified with DPYD2A mutation prior to treatment received fluoropyrimidine-based chemotherapy at reduced initial doses. The average fluoropyrimidine dose intensity during chemotherapy was 50%. No grade ≥3 toxicities were observed. DPYD2A test results were available in an average of 6 days, causing no significant delays in treatment initiation. Conclusion: Upfront genotyping before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD2A. Implications for practice:* Fluoropyrimidines are part of chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. This retrospective analysis demonstrates that upfront genotyping of DPYD before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. This approach was reported previously, but insufficient data concerning its application in real practice are available. This is likely the first reported experience of systematic DPYD genotyping all over Canada and North America as well.
MeSH term(s)	Antimetabolites, Antineoplastic ; Canada ; Capecitabine/adverse effects ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Fluorouracil ; Genotype ; Humans ; Quebec/epidemiology ; Retrospective Studies
Chemical Substances	Antimetabolites, Antineoplastic ; Capecitabine (6804DJ8Z9U) ; Dihydrouracil Dehydrogenase (NADP) (EC 1.3.1.2) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2020-12-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1002/onco.13626
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito